Upregulated expression of transforming growth factor-beta receptors in dermal fibroblasts of skin sections from patients with systemic sclerosis
- PMID: 12465152
Upregulated expression of transforming growth factor-beta receptors in dermal fibroblasts of skin sections from patients with systemic sclerosis
Abstract
Objective: To investigate the expression levels of transforming growth factor-beta (TGF-beta) receptors in the skin of patients with systemic sclerosis (SSc).
Method: We examined expressions of TGF-beta type I and type II receptors (TGF-betaRI and TGF-betaRII) in skin sections of 5 patients with SSc and 5 healthy controls using in situ hybridization and immunohistochemical analysis.
Results: The expression levels of both TGF-betaRI and TGF-betaRII were elevated in the dermal fibroblasts of skin sections from patients with SSc in comparison to control skin sections in in situ hybridization and in immunohistochemical stainings. The numbers of fibroblasts expressing TGF-betaRI and TGF-betaRII in the SSc skin sections were increased in comparison to controls. The inflammatory cells around the vessels also expressed TGF-betaRI and TGF-betaRII intensively in the SSc skin sections.
Conclusion: These results suggest that the autocrine TGF-beta signaling due to the overexpression of TGF-betaRI and TGF-betaRII in dermal fibroblasts is involved in the pathogenesis of dermal fibrosis in patients with SSc.
Similar articles
-
An increased transforming growth factor beta receptor type I:type II ratio contributes to elevated collagen protein synthesis that is resistant to inhibition via a kinase-deficient transforming growth factor beta receptor type II in scleroderma.Arthritis Rheum. 2004 May;50(5):1566-77. doi: 10.1002/art.20225. Arthritis Rheum. 2004. PMID: 15146427
-
Increased levels of transforming growth factor beta receptor type I and up-regulation of matrix gene program: A model of scleroderma.Arthritis Rheum. 2006 Sep;54(9):3011-21. doi: 10.1002/art.22063. Arthritis Rheum. 2006. PMID: 16947635
-
The expression levels and the differential expression of transforming growth factor-beta receptors in dermatofibroma and dermatofibrosarcoma protuberans.Br J Dermatol. 2006 May;154(5):919-25. doi: 10.1111/j.1365-2133.2005.06904.x. Br J Dermatol. 2006. PMID: 16634896
-
Mechanisms of skin fibrosis in systemic sclerosis.J Dermatol. 2010 Jan;37(1):11-25. doi: 10.1111/j.1346-8138.2009.00738.x. J Dermatol. 2010. PMID: 20175837 Review.
-
TGF beta--a role in systemic sclerosis?J Pathol. 1998 Jan;184(1):4-6. doi: 10.1002/(SICI)1096-9896(199801)184:1<4::AID-PATH968>3.0.CO;2-0. J Pathol. 1998. PMID: 9582519 Review.
Cited by
-
Transforming growth factor beta isoforms and TGF-βR1 and TGF-βR2 expression in systemic sclerosis patients.Clin Exp Med. 2023 Jun;23(2):471-481. doi: 10.1007/s10238-022-00841-0. Epub 2022 May 29. Clin Exp Med. 2023. PMID: 35643962
-
TGF-β signaling in health, disease, and therapeutics.Signal Transduct Target Ther. 2024 Mar 22;9(1):61. doi: 10.1038/s41392-024-01764-w. Signal Transduct Target Ther. 2024. PMID: 38514615 Free PMC article. Review.
-
Cellular mechanisms of tissue fibrosis. 8. Current and future drug targets in fibrosis: focus on Rho GTPase-regulated gene transcription.Am J Physiol Cell Physiol. 2014 Jul 1;307(1):C2-13. doi: 10.1152/ajpcell.00060.2014. Epub 2014 Apr 16. Am J Physiol Cell Physiol. 2014. PMID: 24740541 Free PMC article. Review.
-
Autocrine transforming growth factor β signaling regulates extracellular signal-regulated kinase 1/2 phosphorylation via modulation of protein phosphatase 2A expression in scleroderma fibroblasts.Fibrogenesis Tissue Repair. 2010 Dec 6;3:25. doi: 10.1186/1755-1536-3-25. Fibrogenesis Tissue Repair. 2010. PMID: 21134273 Free PMC article.
-
Fibrosis in systemic sclerosis.Rheum Dis Clin North Am. 2008 Feb;34(1):115-43; vii. doi: 10.1016/j.rdc.2007.11.002. Rheum Dis Clin North Am. 2008. PMID: 18329536 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
